Does anyone have a good understanding for how far along the projects are following Saddle Hills?
I ask because the recurring revenue for just Saddle Hills doesn't seem THAT compelling. 64mw x $35k = $2.25M + 10% equity interest (maybe $4M of EBITDA contribution to KPO?). So $6M (plus one-time dev fee). That probably gets them to cash flow neutral on a recurring basis, maybe a little positive. And I know they're aiming for 1H24 for this but based on their execution thus far I think we can all agree 2025 is a better bet.
So to be EBITDA neutral in 2025? Doesn't seem all that exciting. UNLESS I'm underestimating how quickly these other projects are coming down the pike. I just don't get the feeling they're THAT close behind. So then we're talking EBITDA positive in 2026 at the earliest?
Before I get chewed up, I'm not trying to "down ramp" or anything like that. I really like what this company is doing and want to invest. The numbers just need to work and I want to make sure I'm thinking about it the right way. Thanks for any thoughts.
- Forums
- ASX - By Stock
- KPO
- Game on
Game on, page-117
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KPO (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.459M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 17083025 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 25621397 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 17083025 | 0.003 |
12 | 14531167 | 0.002 |
5 | 7890000 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 25621397 | 18 |
0.005 | 6243235 | 5 |
0.006 | 99007 | 1 |
0.007 | 2043125 | 3 |
0.008 | 3100000 | 2 |
Last trade - 16.12pm 15/07/2024 (20 minute delay) ? |
Featured News
KPO (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online